B Pharmacy Sem 4: Pharmaceutical Organic Chemistry III
Subject: Pharmaceutical Organic Chemistry III
1. Aromatic Electrophilic Substitution Reactions (Nitration, Sulfonation, Halogenation, Friedel–Crafts)
2. Aromatic Nucleophilic Substitution Reactions
3. Heterocyclic Chemistry (Five‐ and Six‐Membered Rings; Synthesis & Reactions of Pyrrole, Furan, Thiophene, Pyridine, Quinoline)
4. Chemistry of Steroids and Antibiotics (Structural Features & Key Synthetic Steps)
5. Pharmaceuticals: NSAIDs, Sulfa Drugs & Their Mechanisms
6. Named Organic Reactions & Mechanisms (Wurtz, Sandmeyer, Reimer–Tiemann, etc.)
Unit 1: Aromatic Electrophilic Substitution Reactions
This unit delves into the principles, mechanisms, and pharmaceutical relevance of electrophilic substitution on aromatic rings, covering nitration, sulfonation, halogenation, and Friedel–Crafts reactions.
1.1 Overview & General Mechanism
1.1.1 Definition
Reactions in which an electrophile (E⁺) replaces a hydrogen atom on an aromatic ring without disrupting aromaticity.
1.1.2 Mechanistic Steps
Formation of Electrophile: Generation of a strong electrophile (e.g., NO₂⁺, SO₃H⁺, Cl⁺).
σ‑Complex (Wheland Intermediate): Electrophile attacks the π‐system, forming a resonance‑stabilized arenium ion.
Deprotonation & Aromaticity Restoration: A base removes H⁺ from the σ‑complex, regenerating the aromatic system.
1.1.3 Factors Affecting Reactivity & Orientation
Activating vs. Deactivating Groups:
Activators (–OH, –OCH₃) increase rate, direct ortho/para.
Deactivators (–NO₂, –C≡O) decrease rate, direct meta (unless strongly deactivating).
Steric Effects: Bulky substituents can hinder approach at ortho positions.
1.2 Nitration
1.2.1 Generation of Electrophile
Mixed acid: HNO₃ + H₂SO₄ → NO₂⁺ + HSO₄⁻ + H₂O.
1.2.2 Reaction Conditions & Regioselectivity
Temperature control (0–30 °C) to minimize poly‑nitration.
Activating groups favor ortho/para; deactivators favor meta.
1.2.3 Pharmaceutical Applications
Sulfa Drug Precursors: p‑Aminobenzoic acid nitration → p‑nitrobenzoic acid, reduced to p‑aminobenzoic acid.
Aryl Nitro Intermediates: Building blocks for aniline derivatives in antihistamines.
1.3 Sulfonation
1.3.1 Electrophile Formation
Fuming sulfuric acid (oleum): SO₃ + H₂SO₄ ↔ HSO₃⁺ + HSO₄⁻.
1.3.2 Equilibrium & Reversibility
High temperature drives desulfonation; low temperature (25–50 °C) favors sulfonation.
1.3.3 Uses in Drug Synthesis
Water‑Soluble Salts: Sulfonic acids (e.g., sulfonamide antibiotics) improve aqueous solubility.
Protecting Group Strategy: Temporary sulfonation to block positions during multi‑step syntheses.
1.4 Halogenation
1.4.1 Chlorination & Bromination
Catalyst: FeCl₃ or AlCl₃ for Cl₂; FeBr₃ for Br₂ → generates Cl⁺ or Br⁺.
Selectivity: Activators direct ortho/para; deactivators meta.
1.4.2 Iodination & Fluorination
Iodination: I₂ + oxidizer (HNO₃ or H₂O₂) → I⁺.
Fluorination: More challenging; often uses electrophilic reagents like Selectfluor.
1.4.3 Medicinal Chemistry Relevance
Halogenated Analogs: Modulate lipophilicity, metabolic stability, and receptor binding (e.g., chlorpromazine).
Radiolabeling: I‑131 or F‑18 incorporation for diagnostic imaging.
1.5 Friedel–Crafts Reactions
1.5.1 Alkylation
Electrophile: RCl + AlCl₃ → R⁺.
Limitations: Rearrangement of carbocations; polyalkylation; deactivated rings unreactive.
1.5.2 Acylation
Electrophile: RCOCl + AlCl₃ → RCO⁺.
Advantages: Deactivating acyl group prevents poly‑substitution; can be reduced later to alkyl.
1.5.3 Pharmaceutical Examples
Ketone Intermediates: Acylation to introduce benzoyl motifs in analgesics.
Spiro and Bicyclic Scaffolds: Friedel–Crafts cyclizations in steroid and alkaloid synthesis.
1.6 Key Mechanistic Insights & Named Reactions
1.6.1 Arenium Ion Stability
Resonance forms; substituent effects critical for transition‐state stabilization.
1.6.2 Common Pitfalls
Over‑reaction (polysubstitution), catalyst poisoning (deactivator groups), carbocation rearrangements.
1.6.3 Named Transformations
Gattermann–Koch Formylation (CO + HCl, AlCl₃/CuCl): Introduce –CHO on benzene.
Vilsmeier–Haack Reaction (DMF + POCl₃): Formylation of activated aromatics.
1.7 Key Points for Exams
Draw Mechanisms: Full curved‐arrow mechanism for nitration and Friedel–Crafts acylation.
Predict Products & Orientation: Given substituents, identify major isomer(s).
Pharma Applications: Cite two examples where each type of reaction is used in drug synthesis.
Compare Reactions: Advantages of Friedel–Crafts acylation vs. alkylation.
Troubleshooting: Explain why polyalkylation occurs and strategies to avoid it.
Unit 2: Aromatic Nucleophilic Substitution Reactions
This unit examines how nucleophiles replace leaving groups on aromatic rings, focusing on the two main mechanisms—addition–elimination and benzyne pathways—and their relevance in pharmaceutical synthesis.
2.1 Overview & General Concepts
2.1.1 Definition
Replacement of an aromatic “leaving group” (commonly –NO₂, –Cl, –F) by a nucleophile (Nu⁻) under conditions that preserve or restore aromaticity.
2.1.2 Two Principal Mechanisms
Addition–Elimination (SₙAr): Requires strong electron‑withdrawing groups ortho/para to the leaving group to stabilize the σ‑complex.
Benzyne Mechanism: Occurs under harsh conditions when no activating groups are present; involves elimination to form a highly reactive benzyne intermediate.
2.2 Addition–Elimination (SₙAr)
2.2.1 Mechanistic Steps
Nucleophilic Attack: Nu⁻ attacks the carbon bearing the leaving group, forming a non‑aromatic σ‑complex (Meisenheimer complex).
Elimination: Departure of the leaving group (e.g., Cl⁻, F⁻) restores aromaticity.
2.2.2 Structural Requirements
Activating Groups: Strong electron‑withdrawing substituents (–NO₂, –CN, –SO₂R) at ortho/para positions increase reactivity.
Leaving Groups: Fluoride is often most reactive in SₙAr due to its strong inductive stabilization of the intermediate.
2.2.3 Reaction Conditions
Polar aprotic solvents (DMF, DMSO) to stabilize the nucleophile.
Elevated temperatures (80–150 °C) or phase‑transfer catalysis for sluggish systems.
2.2.4 Pharmaceutical Applications
Sulfonamide Synthesis: Nucleophilic displacement of chlorobenzenes to yield aryl sulfonamides (e.g., sulfamethoxazole).
Radiolabeling: ^18F–fluoride incorporation into aromatic rings for PET tracers via SₙAr on nitroarenes.
2.3 Benzyne Mechanism
2.3.1 Formation of Benzyne
Strong base (NaNH₂, t‑BuOK) induces elimination of HX (often H and a leaving group) to generate a triple‑bonded benzene intermediate.
2.3.2 Nucleophilic Capture
Nu⁻ adds to one of the benzyne carbons; protonation completes substitution, yielding a mixture of regioisomers.
2.3.3 Conditions & Limitations
Requires very strong bases and high temperatures (>200 °C).
Poor regioselectivity—often yields ortho and meta substituted isomers.
2.3.4 Drug Industry Examples
Aniline Synthesis: Historical route to aniline derivatives via benzyne from chlorobenzene; largely supplanted by milder methods.
Polymer Precursors: Manufacturing of specialty monomers where traditional SₙAr fails.
2.4 Practical Considerations & Variations
2.4.1 Leaving‑Group Effects
Order of reactivity: F > Cl > Br > I for SₙAr (opposite to electrophilic halogenations).
2.4.2 Nucleophile Types
Common nucleophiles: alkoxides (–OR), amines (–NH₂), thiolates (–SR), cyanide (–CN).
2.4.3 Catalytic & Phase‑Transfer Methods
Use of crown ethers or quaternary ammonium salts to transport inorganic nucleophiles into organic phase.
2.5 Key Points for Exams
Mechanism Diagrams: Draw curved‑arrow mechanisms for both addition–elimination and benzyne pathways.
Predict Reactivity: Given a substituted aryl halide, rank its susceptibility to SₙAr.
Regioselectivity Rationale: Explain how ortho/para nitro groups direct and stabilize the Meisenheimer complex.
Pharma Examples: Cite one SₙAr route to an important sulfonamide and one ^18F‑labeling procedure.
Compare Mechanisms: List pros and cons of addition–elimination vs. benzyne in drug synthesis.
Unit 3: Heterocyclic Chemistry
A comprehensive exploration of five‐ and six‐membered heterocycles—focusing on their structures, methods of synthesis, characteristic reactions, and roles in pharmaceutical compounds.
3.1 Introduction to Heterocyclic Chemistry
3.1.1 Definition & Importance
Heterocycles are ring systems containing one or more heteroatoms (N, O, S) alongside carbon.
Over 75% of small‐molecule drugs feature heterocyclic scaffolds—crucial for binding specificity, solubility, and metabolic stability.
3.1.2 Classification
By Ring Size:
Five‑membered: Pyrrole, Furan, Thiophene
Six‑membered: Pyridine, Quinoline (fused benzopyridine)
By Saturation: Aromatic vs. partially or fully saturated analogs (e.g., piperidine, tetrahydrofuran).
3.1.3 Aromaticity Criteria
Planarity, cyclic conjugation, and Huckel’s rule (4n + 2 π‑electrons) determine aromatic stability.
3.2 Pyrrole
3.2.1 Structure & Properties
Formula C₄H₅N; 6 π‑electron aromatic ring with the lone pair on N delocalized into the π‑system.
Relatively acidic N–H (pKa ≈ 17) and highly activated at the 2‑ and 5‑positions for electrophilic substitution.
3.2.2 Key Syntheses
Paal–Knorr Synthesis
1,4‑Diketone + ammonia or primary amine → pyrrole (acid‐catalyzed cyclization).
Hantzsch Synthesis Variation
α‑Amino ketone + α,β‑unsaturated carbonyl → pyrrole under acidic conditions.
3.2.3 Reactions
Electrophilic Substitution:
Nitration, halogenation occur at C‑2/C‑5 under mild conditions.
Metalation:
Lithiation at C‑2 allows for further cross‑coupling or alkylation.
Oxidation:
Over‐oxidation yields maleimide derivatives; controlled oxidation leads to functionalized pyrroles.
3.2.4 Pharmaceutical Relevance
Prostaglandins: Contain a 5‑membered ring related to pyrrole.
Anticancer Agents: E.g., select kinase inhibitors use substituted pyrrole cores.
3.3 Furan
3.3.1 Structure & Properties
Formula C₄H₄O; oxygen’s lone pair partly participates in aromatic sextet.
More reactive than benzene toward electrophiles; instability under strong acid or heat.
3.3.2 Syntheses
Paal–Knorr Furan Synthesis
1,4‑Diketone cyclodehydration under acid or base.
Feist–Benary Reaction
α‑Halocarbonyl + β‑dicarbonyl + amine catalysis yields substituted furans.
3.3.3 Reactions
Diels–Alder Donor:
Acts as a diene in cycloadditions to build complex ring systems.
Electrophilic Substitution:
Occurs at C‑2, yielding 2‑substituted furans (e.g., formylation, halogenation).
Ring Opening:
Acidic or catalytic hydrogenation can open the ring to 1,4‑dicarbonyls.
3.3.4 Pharmaceutical Uses
Antimicrobials: Nitrofurans (e.g., nitrofurantoin) rely on furan’s redox chemistry.
Cardiovascular Drugs: Some calcium‐channel blockers incorporate furan units.
3.4 Thiophene
3.4.1 Structure & Properties
Formula C₄H₄S; sulfur contributes two electrons to aromatic sextet, conferring high stability.
Electron‐rich yet less reactive than furan; resistant to strong acids.
3.4.2 Synthetic Routes
Paal–Knorr Thiophene Synthesis
1,4‑Diketone + P₄S₁₀ (thionation) → thiophene.
Gewald Reaction
α‑Cyano ketone + elemental sulfur + base → 2‑aminothiophenes.
3.4.3 Characteristic Reactions
Electrophilic Substitution:
Predominantly at C‑2; nitration, sulfonation, and halogenation under controlled conditions.
Metal‑Catalyzed Coupling:
Suzuki, Stille, or Negishi cross‑coupling at halogenated thiophenes to build conjugated systems.
3.4.4 Drug Applications
Antipsychotics & Antidepressants: E.g., many carry substituted thiophene rings for CNS activity.
Anti‑inflammatories: Some COX‑2 inhibitors include thiophene moieties.
3.5 Pyridine
3.5.1 Structure & Properties
Formula C₅H₅N; six‑membered aromatic ring where N’s lone pair resides in an sp² orbital (not part of π‑system)—accounts for basicity (pKa of conjugate acid ≈ 5.2).
Deactivated toward electrophiles, activated toward nucleophiles at ortho/para positions.
3.5.2 Synthesis Methods
Hantzsch Dihydropyridine Synthesis
Aldehyde + two β‑ketoesters + ammonia → dihydropyridine → oxidized to pyridine.
Bönnemann Cyclization
1,5‑Diketones + ammonia/trityl salts under heat.
3.5.3 Reaction Chemistry
Electrophilic Substitution:
Requires strong Lewis acids; often leads to N‑oxide intermediates for further functionalization.
Nucleophilic Substitution:
2‑ and 4‑positions can undergo SₙAr when converted to N‑oxide or with strong leaving groups.
Quaternization:
Formation of pyridinium salts—used as phase‑transfer catalysts or medicinal scaffolds.
3.5.4 Pharmaceutical Significance
Antituberculars: Isoniazid analogs feature hydrazide‐pyridine cores.
Cardiovascular Agents: Nicotinic acid (niacin) is a pyridine‐3‐carboxylic acid.
3.6 Quinoline
3.6.1 Structure & Properties
Fused benzene–pyridine system (C₉H₇N); aromatic in both rings with resonance across the bicyclic structure.
Basicity similar to pyridine; electrophilic and nucleophilic reactivity localized to the pyridine ring.
3.6.2 Synthetic Strategies
Skraup Synthesis
Aniline + glycerol + H₂SO₄ + oxidant (nitrobenzene) → quinoline.
Friedländer Synthesis
2‑Aminoaryl ketone + carbonyl compound with α‑methylene → quinoline under acidic/basic catalysis.
3.6.3 Reactions & Functionalization
Electrophilic Substitution:
Occurs primarily on the benzene ring; directed by pyridine nitrogen’s -I effect.
Nucleophilic Addition at C‑2:
Grignard or organolithium reagents attack C‑2 of N‑oxide derivatives.
3.6.4 Role in Drug Design
Antimalarials: Quinine and chloroquine belong to quinoline family.
Antibacterials & Antineoplastics: Many exhibit intercalating or enzyme‑inhibitory activity through planar quinoline cores.
3.7 Comparative Summary & Applications
Heterocycle | Aromaticity | Key Reactivity | Pharma Examples |
---|---|---|---|
Pyrrole | 6 π e– | Electrophilic (C‑2) | Prostaglandins, kinase inhibitors |
Furan | 6 π e– | Diels–Alder, C‑2 EAS | Nitrofurans, calcium‑channel blockers |
Thiophene | 6 π e– | C‑2 EAS, coupling | Antipsychotics, COX‑2 inhibitors |
Pyridine | 6 π e– | Nucleophilic (C‑2/4) | Isoniazid, niacin |
Quinoline | 10 π e– | Benzene EAS, N‑oxide | Quinine, chloroquine, anticancer intercalators |
3.8 Key Points for Exams
Mechanism Sketches: Show Paal–Knorr pyrrole synthesis, Skraup quinoline formation, and a Diels–Alder with furan.
Reactivity Trends: Rank five heterocycles by ease of electrophilic substitution.
Synthetic Design: Propose a route to 2‑aminothiophene using the Gewald reaction.
Pharmaceutical Context: Match five heterocycles to their corresponding drug example and discuss why that ring was chosen.
Aromaticity Rationalization: Explain why pyrrole’s lone pair contributes to aromaticity, whereas pyridine’s does not.
Unit 5: Pharmaceuticals – NSAIDs, Sulfa Drugs & Their Mechanisms
An extensive examination of non‑steroidal anti‑inflammatory drugs (NSAIDs) and sulfonamide (sulfa) antibiotics, covering their chemical structures, mechanisms of action, pharmacokinetics, therapeutic uses, adverse effects, and medicinal chemistry considerations.
5.1 Non‑Steroidal Anti‑Inflammatory Drugs (NSAIDs)
5.1.1 Overview & Classification
Definition: Drugs that relieve pain, reduce inflammation, and lower fever by inhibiting cyclooxygenase enzymes (COX‑1 and COX‑2), thereby decreasing prostaglandin synthesis.
Major Classes:
Salicylates: e.g., aspirin (acetylsalicylic acid)
Propionic Acid Derivatives: e.g., ibuprofen, naproxen
Acetic Acid Derivatives: e.g., diclofenac, indomethacin
Oxicams: e.g., piroxicam, meloxicam
COX‑2 Selective Inhibitors (Coxibs): e.g., celecoxib, etoricoxib
5.1.2 Mechanism of Action
5.1.2.1 Cyclooxygenase (COX) Isoforms
COX‑1: Constitutive enzyme involved in homeostatic functions (gastric mucosal protection, platelet aggregation, renal blood flow).
COX‑2: Inducible enzyme upregulated during inflammation; also constitutively expressed in some tissues (kidney, vascular endothelium).
5.1.2.2 Inhibition Kinetics
Aspirin: Irreversible acetylation of Ser530 (COX‑1) and Ser516 (COX‑2) → permanent inactivation in platelets.
Reversible Inhibitors: Ibuprofen and most others bind non‑covalently; duration dependent on plasma half‑life.
COX‑2 Selectivity: Bulkier side‑chains exploit a secondary pocket in COX‑2’s active site for selective binding.
5.1.3 Structure–Activity Relationships (SAR)
5.1.3.1 Salicylates
Aspirin: 2‑acetoxybenzoic acid; acetyl group critical for irreversible COX acetylation.
Diflunisal: 4′‑fluoro substitution increases potency and half‑life.
5.1.3.2 Propionic Acids
Ibuprofen: α‑methyl group enhances stereoselective COX binding; S‑enantiomer more active.
Naproxen: Secondary carboxylate and naphthyl moiety increase lipophilicity and duration.
5.1.3.3 Acetic Acids
Diclofenac: Two ortho‑chloro substituents on phenyl rings improve potency but also GI toxicity.
Indomethacin: Indole acetic acid scaffold with bulky p‑chlorobenzoyl group for high affinity.
5.1.3.4 Oxicams & Coxibs
Piroxicam: Enolic OH chelates active‑site Arg120 in COX.
Celecoxib: Diaryl‑substituted pyrazole core; sulfonamide moiety binds COX‑2 selectivity pocket.
5.1.4 Pharmacokinetics & Metabolism
5.1.4.1 Absorption & Distribution
Rapid GI absorption; high plasma protein binding (>90%).
Volume of distribution influenced by lipophilicity (e.g., naproxen more lipophilic than aspirin).
5.1.4.2 Metabolism
Phase I: Hepatic oxidation by CYP2C9 (diclofenac, celecoxib) or esterases (aspirin → salicylate).
Phase II: Conjugation (glucuronidation, sulfation) → inactive metabolites excreted renally.
5.1.4.3 Elimination
Half‑lives vary widely: aspirin (~0.3 h), ibuprofen (~2 h), naproxen (~14 h), piroxicam (~50 h).
Renal excretion of free drug and conjugates; dose adjustment in renal impairment.
5.1.5 Therapeutic Uses & Adverse Effects
5.1.5.1 Indications
Analgesia (mild–moderate pain), antipyresis, anti‑inflammation (arthritis, dysmenorrhea), cardiovascular prophylaxis (low‑dose aspirin).
5.1.5.2 Adverse Effects
Gastrointestinal: Gastric ulceration, bleeding (due to COX‑1 inhibition and decreased prostaglandins).
Renal: Reduced renal perfusion, electrolyte imbalance (sodium retention, hyperkalemia).
Cardiovascular: Hypertension exacerbation; increased risk of MI/stroke with COX‑2 inhibitors.
Hypersensitivity: Asthma exacerbation (aspirin‑induced), skin reactions.
5.1.5.3 Mitigation Strategies
Co‑administration of proton‑pump inhibitors or misoprostol.
Use of lowest effective dose; selective COX‑2 inhibitors in high GI‑risk patients.
5.2 Sulfonamide (Sulfa) Drugs
5.2.1 Historical Perspective & Overview
First effective systemic antibacterial agents; prontosil (azo‑prodrug) → sulfanilamide active metabolite.
Backbone: para‑aminobenzenesulfonamide structure mimics para‑aminobenzoic acid (PABA).
5.2.2 Mechanism of Action
5.2.2.1 Competitive Inhibition of Dihydropteroate Synthase (DHPS)
PABA Analogue: Sulfonamides compete with PABA for DHPS, blocking folate synthesis in bacteria (humans obtain folate from diet).
Bacteriostatic Effect: Inhibition of dihydrofolic acid formation → decreased nucleotide synthesis → halted DNA replication.
5.2.2.2 Synergism with Trimethoprim
Combined therapy (co‑trimoxazole) sequentially blocks DHPS and dihydrofolate reductase → bactericidal synergy.
5.2.3 Chemical Variations & SAR
5.2.3.1 Classical Sulfonamides
Sulfanilamide: p‑NH₂–C₆H₄–SO₂–NH₂ core; minimal side‑chain toxicity.
Sulphadiazine: Heterocyclic substituent (pyrimidine) at NH enhances spectrum.
5.2.3.2 Long‑Acting & Topical Agents
Sulfadoxine: p‑Methoxy at para‑amino → long half‑life (100 h) for malaria prophylaxis.
Sulfacetamide: Water‑soluble derivative for ophthalmic infections.
Silver Sulfadiazine: Topical burn ointment; silver provides additional antimicrobial action.
5.2.3.3 Solubility & Potency Modifications
Para‑substitution (alkyl, aryl) tunes lipophilicity and pharmacokinetics.
N₁‑acetylation in vivo → crystalluria risk; adjust dose and hydration.
5.2.4 Pharmacokinetics & Metabolism
5.2.4.1 Absorption & Distribution
Well‑absorbed orally; wide tissue distribution including CNS (e.g., sulfisoxazole crosses BBB).
High plasma protein binding (~90%) – potential for displacement interactions.
5.2.4.2 Metabolism
Acetylation (NAT enzymes) in liver → N¹‑acetyl metabolites (inactive, less water‑soluble).
Glucuronidation of –OH or –NH groups.
5.2.4.3 Elimination
Excreted primarily by kidney; both parent drug and metabolites.
Prolonged half‑life in neonates and elderly due to reduced renal function; monitor dosing.
5.2.5 Therapeutic Uses & Toxicity
5.2.5.1 Indications
Urinary tract infections, respiratory infections, certain protozoal diseases (e.g., toxoplasmosis, malaria prophylaxis).
Combined with trimethoprim for Pneumocystis jirovecii pneumonia in HIV.
5.2.5.2 Adverse Reactions
Hypersensitivity: Rash, Stevens–Johnson syndrome, toxic epidermal necrolysis.
Hematologic: Hemolytic anemia in G6PD deficiency; agranulocytosis, aplastic anemia.
Crystalluria: N¹‑acetyl sulfonamide precipitation in renal tubules—hydrate patients.
Kernicterus: Displacement of bilirubin in neonates—contraindicated in late pregnancy and infants.
5.3 Key Medicinal Chemistry Strategies
Prodrug Design: Prontosil’s azo linkage → activated in vivo to sulfanilamide; aspirin’s acetyl group → salicylic acid.
Selectivity Tuning: COX‑2 selectivity via steric bulk; sulfonamide spectrum via heterocycle variation.
Toxicity Mitigation: Minimizing reactive metabolites (e.g., diclofenac → quinone imines), optimizing solubility to prevent crystalluria.
5.4 Key Points for Exams
Draw Mechanisms: Show aspirin’s acetylation of COX‑1 serine and sulfonamide competition with PABA at DHPS.
Compare Classes: List three differences between propionic acid NSAIDs and acetic acid NSAIDs in terms of SAR and toxicity.
Case Study: Explain why celecoxib has lower GI toxicity but higher cardiovascular risk.
Design Problem: Propose a para‑substituent to enhance sulfonamide solubility and justify choice.
Clinical Correlation: Describe co‑trimoxazole’s synergistic mechanism and clinical indications.
Unit 6: Named Organic Reactions & Mechanisms
This unit surveys classic named transformations—detailing mechanisms, conditions, scope, and pharmaceutical applications of key reactions such as Wurtz, Sandmeyer, Reimer–Tiemann, and others.
6.1 Wurtz Reaction
6.1.1 Reaction Overview
Definition: Coupling of two alkyl halides (R–X) in sodium metal/ether to form a higher alkane (R–R).
General Equation:
2 R–X + 2 Na → R–R + 2 NaX
6.1.2 Mechanism
Single‐Electron Transfer (SET): Na donates an electron to R–X → R· (radical) + NaX
Radical Coupling: Two R· radicals recombine → R–R
Side Pathways: R· + R–X → R–X + R· (chain); formation of mixed coupling products with two different halides.
6.1.3 Reaction Conditions & Limitations
Solvent: Dry diethyl ether to stabilize radicals and solvated sodium.
Substrate Scope: Best for primary halides; secondary/tertiary give poor yields due to rearrangements and elimination.
Major Drawback: Poor selectivity—statistical mixture if two different R–X used.
6.1.4 Pharmaceutical Relevance
Historical use in constructing symmetrical alkyl chains in lipid‐mimetic drug carriers.
Nowadays largely of pedagogical interest; replaced by more selective coupling (e.g., Grignard, Suzuki).
6.2 Sandmeyer Reaction
6.2.1 Reaction Overview
Definition: Replacement of an aryl diazonium salt with halide or pseudohalide via copper(I) catalysis.
General Transformations:
Ar–N₂⁺ Cl⁻ + CuCl → Ar–Cl
Ar–N₂⁺ Br⁻ + CuBr → Ar–Br
Ar–N₂⁺ + CuCN → Ar–CN
6.2.2 Mechanism
Diazonium Formation: Ar–NH₂ + NaNO₂ + HCl → Ar–N₂⁺ Cl⁻
Copper(I)–Mediated SET: Cu(I) reduces Ar–N₂⁺ → Ar· + N₂ + Cu(II)
Radical Capture: Ar· + Cu(II)–X → Ar–X + Cu(I)
6.2.3 Conditions & Variations
Temperature: 0–5 °C for diazotization; reaction warmed for coupling.
Scope: Introduce Cl, Br, CN, SCN, OH (via Cu₂O/H₂O), etc.
Limitations: Sensitive to functional groups that react with radicals; competing phenol formation under aqueous conditions.
6.2.4 Pharmaceutical Applications
Synthesis of aryl nitriles (–CN) as precursors for heterocycles (e.g., pyridines) in drug scaffolds.
Preparation of halogenated aromatics for further cross‐coupling (e.g., Suzuki–Miyaura).
6.3 Reimer–Tiemann Reaction
6.3.1 Reaction Overview
Definition: Formylation of phenols at ortho positions using chloroform and base to yield salicylaldehydes.
General Equation:
Ar–OH + CHCl₃ + 3 KOH → Ar–(2‑CHO) + 3 KCl + H₂O
6.3.2 Mechanism
Carbene Generation: CHCl₃ + OH⁻ → :CCl₃ + Cl⁻ + H₂O
Electrophilic Attack: :CCl₃ attacks ortho position of phenoxide → dichlorocarbene adduct.
Hydrolysis & Dechlorination: Base‐mediated removal of Cl’s → formyl group.
6.3.3 Reaction Conditions & Regioselectivity
Base: Strong (KOH or NaOH), often in aqueous/alcoholic medium.
Temperature: Reflux for several hours.
Selectivity: Ortho favored by coordination of phenoxide; para product minor unless ortho blocked.
6.3.4 Pharmaceutical Uses
Preparation of salicylaldehyde derivatives—key intermediates for Schiff base drugs and flavoring agents.
Building block for coumarin synthesis via subsequent Perkin or Knoevenagel reactions.
6.4 Other Key Named Reactions
6.4.1 Friedländer Synthesis
Purpose: Construction of quinoline rings by condensation of 2‑aminobenzaldehyde with ketones bearing α‑methylene.
Mechanism: Schiff base → intramolecular aldol condensation → dehydration → quinoline.
6.4.2 Kolbe–Schmitt Reaction
Purpose: Carboxylation of phenolates to yield salicylic acids (e.g., aspirin precursor).
Mechanism: CO₂ under pressure (100–200 atm) at 125–150 °C attacks phenoxide at ortho → salicylate → acidification.
6.4.3 Gabriel Phthalimide Synthesis
Purpose: Preparation of primary amines: phthalimide + KOH → phthalimide anion + R–X → phthalimide‑N‑alkyl → hydrazinolysis → R–NH₂.
Mechanism: SN2 on phthalimide anion; followed by deprotection.
6.4.4 Clemmensen Reduction & Wolff–Kishner Reduction
Clemmensen: Acidic Zn/Hg reduction of ketones to alkanes.
Wolff–Kishner: Base‐promoted hydrazone → diimide → alkane.
Pharma Use: Selective removal of carbonyl functionalities in complex drug intermediates.
6.4.5 Michael Addition
Purpose: Conjugate addition of nucleophiles (enolates, thiols, amines) to α,β‑unsaturated carbonyls.
Mechanism: Nucleophile adds to β‑carbon → enolate → protonation.
Utility: C–C bond formation in steroid side‑chain elaboration and heterocycle synthesis.
6.5 Comparative Mechanistic Insights
Reaction | Key Intermediate | Conditions | Pharma Application |
---|---|---|---|
Wurtz | Alkyl Radical (R·) | Na, ether | Lipid‐chain coupling (historical) |
Sandmeyer | Aryl Radical (Ar·) | Cu(I), diazonium | Aryl–CN and halide synthesis |
Reimer–Tiemann | Dichlorocarbene (:CCl₃) | CHCl₃, KOH, reflux | Salicylaldehyde intermediates |
Kolbe–Schmitt | Carboxylate Anion | CO₂ (high P, T) | Salicylic acid (aspirin precursor) |
Michael Addition | Enolate | Base, polar solvents | C–C bond formation in steroids, heterocycles |
6.6 Key Points for Exams
Mechanism Drawings: Show full curved‐arrow for Sandmeyer and Reimer–Tiemann.
Condition Rationale: Explain why Reimer–Tiemann requires chloroform/strong base but Kolbe–Schmitt uses CO₂/pressure.
Selectivity Discussion: Compare ortho vs. para carboxylation in Kolbe–Schmitt and Reimer–Tiemann.
Pharma Examples: For each reaction, name one drug or intermediate synthesized via that route.
Limitation Solutions: Propose modern alternatives (e.g., Pd‐catalyzed couplings vs. Wurtz).